ResMed has announced the launch of its ResMed Air Solutions range, led by the intelligent, cloud-enabled AirCurve 10 CS PaceWave with AirView system. This is the first device to combine remote monitoring with ResMed’s PaceWave minute ventilation (MV)-adaptive-servo-ventilation (ASV) therapy. Through a unique patented algorithm, PaceWave MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, offering an option to treat a wide variety of patients with central sleep apnoea.
The use of PaceWave MV-ASV therapy to treat central sleep apnoea in patients with chronic heart failure is currently being investigated in SERVE-HF, the world’s largest randomised trial in this field.
Commenting on the launch of ResMed’s Air Solutions, Anne Reiser, president of ResMed Europe and Asia Pacific, says: “The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave with AirView represents a landmark shift in the treatment of central sleep apnoea. By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services. This launch may also have significant implications for many patients with chronic heart failure. The findings of the SERVE-HF study will indicate the scale of benefit PaceWave MV-ASV may bring but there is real potential for a step-change on how we prioritise breathing management in this patient population.”
